[ NATIONAL · GB ]
A post-EU-exit regime that retained EU-derived requirements and now diverges from them selectively.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
EUROPE
The Human Medicines Regulations 2012 (SI 2012 No. 1916) are the principal instrument for human medicines in the United Kingdom. Part 3, “Manufacture and distribution of medicinal products and active substances”, carries the licensing regime; its Chapter 2, “Manufacturing and wholesale dealing”, runs from regulation 17 to regulation 45AB and covers the grant of licences, the conditions attached to holding a manufacturer’s licence and a wholesale dealer’s licence, and the offences that attach to operating without one.
Through a licence held by a named site, and inspection against it. The MHRA issues a manufacturer’s/importer’s licence, a manufacturer’s “specials” licence for unlicensed medicines made to order, a manufacturer’s licence for investigational medicinal products, and a wholesale distribution licence. The agency publishes the standards it inspects against in two reference works practitioners cite by colour rather than by title: the Orange Guide for good manufacturing and distribution practice, and the Green Guide for wholesale distribution.
WHAT TRANSFERS
Less than it did, and the direction of travel is the thing to watch. The UK left the EU single market with a body of EU-derived requirements retained in domestic law, so the text a practitioner reads is still substantially familiar — but it is now UK law that can be amended without reference to Brussels, and divergence is selective rather than absent. The UK’s participation in ICH and in PIC/S is what keeps mutual confidence in inspection outcomes alive; neither is a substitute for holding the right domestic licence, and no amount of alignment removes the requirement for one.
The four licence types are not interchangeable. Making an unlicensed medicine to a prescriber’s order, making an investigational product for a trial, and making a licensed product for market are separate permissions with separate conditions, and operating outside the one you hold is an offence under Part 3 rather than a compliance observation.
Requirements inherited at exit are the starting point, not a standing answer. Anything time-sensitive — a deadline, a transition, a labelling requirement — has to be read against the current UK instrument rather than against its EU ancestor or against a colleague’s memory of it.
It is the compilation the MHRA inspects against, so it is the document to reconcile a site’s procedures with. Practitioners who work only from the underlying regulations tend to miss the expectations the guide sets out in detail.
Part 3 covers manufacture and distribution of active substances, not only of finished medicinal products. Registration obligations sit upstream of the finished-product licence and are a recurring blind spot for organisations that think of themselves as buyers rather than as handlers.
The Human Medicines Regulations 2012, SI 2012 No. 1916. Part 3 covers manufacture and distribution of medicinal products and active substances, and its Chapter 2 — regulations 17 to 45AB — sets out manufacturing and wholesale dealing, including the grant of licences and the conditions for holding a manufacturer’s licence or a wholesale dealer’s licence.
A manufacturer’s/importer’s licence, a manufacturer’s “specials” licence for unlicensed medicines made to order, a manufacturer’s licence for investigational medicinal products, and a wholesale distribution licence. They are distinct permissions with distinct conditions rather than tiers of one licence.
The MHRA’s published compilation of good manufacturing practice and good distribution practice guidance — the standard UK inspections are conducted against. The Green Guide is its counterpart for wholesale distribution. Both are guidance; the enforceable requirements sit in the Human Medicines Regulations 2012.
Not by itself. Participation in PIC/S and in ICH supports mutual confidence in inspection outcomes and in technical requirements, but it does not license a site. A manufacturer or wholesale dealer operating in the UK needs the relevant UK licence under Part 3 of the Regulations regardless of what it holds elsewhere.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about United Kingdom: requirements still arrive through the authorities below, and the edition in force is theirs to state.
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.